JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB181131

Anti-PTGR1 antibody [EPR13451-10]

Be the first to review this product! Submit a review

|

(4 Publications)

Rabbit Recombinant Monoclonal PTGR1 antibody. Suitable for WB and reacts with Human samples. Cited in 4 publications.

View Alternative Names

LTB4DH, PTGR1, Prostaglandin reductase 1, PRG-1, 15-oxoprostaglandin 13-reductase, Dithiolethione-inducible gene 1 protein, Leukotriene B4 12-hydroxydehydrogenase, NAD(P)H-dependent alkenal/one oxidoreductase, D3T-inducible gene 1 protein, DIG-1

3 Images
Western blot - Anti-PTGR1 antibody [EPR13451-10] (AB181131)
  • WB

Supplier Data

Western blot - Anti-PTGR1 antibody [EPR13451-10] (AB181131)

All lanes:

Western blot - Anti-PTGR1 antibody [EPR13451-10] (ab181131) at 1/1000 dilution

All lanes:

HeLa cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

Predicted band size: 35 kDa

Observed band size: 36 kDa

false

Western blot - Anti-PTGR1 antibody [EPR13451-10] (AB181131)
  • WB

Supplier Data

Western blot - Anti-PTGR1 antibody [EPR13451-10] (AB181131)

All lanes:

Western blot - Anti-PTGR1 antibody [EPR13451-10] (ab181131) at 1/2000 dilution

All lanes:

HT-29 cell lysate at 20 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution

Predicted band size: 35 kDa

Observed band size: 36 kDa

false

Western blot - Anti-PTGR1 antibody [EPR13451-10] (AB181131)
  • WB

Lab

Western blot - Anti-PTGR1 antibody [EPR13451-10] (AB181131)

Lanes 1-2 : Merged signal (red and green). Green - ab181131 observed at 38 kDa. Red - loading control ab7291 observed at 50 kDa.

ab181131 Anti-PTGR1 antibody [EPR13451-10] was shown to specifically react with PTGR1 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265169 (knockout cell lysate ab258152) was used. Wild-type and PTGR1 knockout samples were subjected to SDS-PAGE. ab181131 and Anti-alpha Tubulin antibody [DM1A] - Loading Control (ab7291) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-PTGR1 antibody [EPR13451-10] (ab181131) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

PTGR1 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human PTGR1 knockout HeLa cell line (<a href='/en-us/products/cell-lines/human-ptgr1-knockout-hela-cell-line-ab265169'>ab265169</a>)

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 35 kDa

Observed band size: 38 kDa

false

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR13451-10

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/2000", "WB-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purity
Tissue culture supernatant
Storage buffer
Preservative: 0.01% Sodium azide Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PTGR1 also known as Prostaglandin Reductase 1 acts as an enzyme within cellular metabolism. It functions by catalyzing the reduction of prostaglandins namely converting 15-keto-prostaglandins to their respective 1314-dihydro metabolites. PTGR1 has a molecular mass of approximately 35 kDa. This enzyme primarily expresses in liver tissues but it is present in other tissues like the lungs and kidneys as well.
Biological function summary

PTGR1 participates in metabolizing prostaglandins which play important roles in inflammation and homeostasis. It does not form part of a larger protein complex but works independently to control the levels of active prostaglandins within cells. This activity regulates physiological processes such as inflammation and vascular tone.

Pathways

Prostaglandin metabolism involves PTGR1's function. It integrates into the arachidonic acid pathway. Within this pathway PTGR1 interacts with other enzymes such as cyclooxygenases and lipoxygenases orchestrating the catabolism of prostaglandins and related lipid compounds. This coordination maintains the balance of inflammatory responses.

PTGR1 contributes significantly to inflammatory conditions and cancer. Elevated or altered PTGR1 activity associates with various inflammatory diseases due to its role in prostaglandin catabolism. Additionally in some cancer types abnormal prostaglandin levels mediated by PTGR1 affect tumor growth. The enzyme's participation in these processes links it to proteins such as COX-2 which is critical for prostaglandin synthesis and inflammation.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

NAD(P)H-dependent oxidoreductase involved in metabolic inactivation of pro- and anti-inflammatory eicosanoids : prostaglandins (PG), leukotrienes (LT) and lipoxins (LX) (PubMed : 25619643). Catalyzes with high efficiency the reduction of the 13,14 double bond of 15-oxoPGs, including 15-oxo-PGE1, 15-oxo-PGE2, 15-oxo-PGF1-alpha and 15-oxo-PGF2-alpha (PubMed : 25619643). Catalyzes with lower efficiency the oxidation of the hydroxyl group at C12 of LTB4 and its derivatives, converting them into biologically less active 12-oxo-LTB4 metabolites (By similarity) (PubMed : 25619643). Reduces 15-oxo-LXA4 to 13,14 dihydro-15-oxo-LXA4, enhancing neutrophil recruitment at the inflammatory site (By similarity). May play a role in metabolic detoxification of alkenals and ketones. Reduces alpha,beta-unsaturated alkenals and ketones, particularly those with medium-chain length, showing highest affinity toward (2E)-decenal and (3E)-3-nonen-2-one (PubMed : 25619643). May inactivate 4-hydroxy-2-nonenal, a cytotoxic lipid constituent of oxidized low-density lipoprotein particles (By similarity).
See full target information PTGR1

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Scientific reports 14:27448 PubMed39523403

2024

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.

Applications

IHC-P

Species

Human

Dag Rune Stormoen,Signe Lehn,Kent W Mouw,Zoltan Szallasi,Linea Cecilie Melchior,Line Hammer Dohn,Judit Börcsok,Maria Rossing,Birgitte Grønkaer Toft,Helle Pappot

Scientific reports 13:20567 PubMed37996508

2023

Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Aurel Prosz,Haohui Duan,Viktoria Tisza,Pranshu Sahgal,Sabine Topka,Gregory T Klus,Judit Börcsök,Zsofia Sztupinszki,Timothy Hanlon,Miklos Diossy,Laura Vizkeleti,Dag Rune Stormoen,Istvan Csabai,Helle Pappot,Joseph Vijai,Kenneth Offit,Thomas Ried,Nilay Sethi,Kent W Mouw,Sandor Spisak,Shailja Pathania,Zoltan Szallasi

Stem cells international 2023:2826815 PubMed37964983

2023

A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories.

Applications

Unspecified application

Species

Unspecified reactive species

Guanghao Zhang,Xiaolong Xu,Luojiang Zhu,Sisi Li,Rundong Chen,Nan Lv,Zifu Li,Jing Wang,Qiang Li,Wang Zhou,Pengfei Yang,Jianmin Liu

International journal of molecular sciences 21: PubMed32102467

2020

Analysis and Identification of Tumorigenic Targets of MicroRNA in Cancer Cells by Photoreactive Chemical Probes.

Applications

Unspecified application

Species

Unspecified reactive species

Zhiyu Su,Tsogzolmaa Ganbold,Huricha Baigude
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com